Recently Featured

Cancer, immune drugmakers dominate VC funding so far in 2026

August 13, 2026
Drug developers focusing on either cancer or immunology have accounted for over 40% of the total biotech companies and capital raised in 2026, according to data from BioPharma Dive. This significant concentration of funding highlights the ongoing prioritization of these therapeutic areas within the venture capital landscape, reflecting a sustained investor interest in innovative treatments…

Greater Boston’s Job Losses Prompt Rise of Unlikely Biotech Hubs

August 13, 2026
As Greater Boston’s biotech industry sheds jobs, three unlikely regions—Las Vegas, Oklahoma, and Pennsylvania—are emerging as promising new hubs for biotechnology. This shift comes amid a broader trend of companies reevaluating their operational footprints in response to economic pressures and changing market dynamics. While Boston has long been regarded as the epicenter of biotech innovation,…

Novartis Invests $1.1 Billion in Myricx Bio to Enhance ADC Pipeline

August 13, 2026
Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload, as reported by Fierce Biotech. The Swiss pharma company has been slower to adopt ADCs compared to its peers, but this acquisition signals a strategic shift. Myricx, based in London, is…

The race for an Ebola therapy begins

August 12, 2026
The global pharmaceutical industry is witnessing an intensified race to develop effective therapies for Ebola, spurred by recent outbreaks and the urgent need for improved treatment options. The World Health Organization has reported a resurgence of Ebola cases, highlighting the critical gaps in current therapeutic strategies and the necessity for innovative solutions that can be…

Ongoing Cases